Catalyst Brief

← Calendar

Readoutin 104d

Merz Therapeutics GmbH — Xeomin

Phase 3 primary completion: A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine.

Date
Mar 2027
Type
Readout
Indication
Chronic Migraine

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Merz Therapeutics GmbH

  1. Mar2027